Last updated on September 2018

Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative ER-positive Her2-negative Breast Cancer


Brief description of study

The purpose of this study is to compare the safety and efficacy of epirubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide in lymph node negative, estrogen receptor (ER) positive, human epithelial growth factor receptor 2 (HER2) negative breast cancer patients as adjuvant chemotherapy.

Detailed Study Description

This is a non-inferiority study. According to previous study results, the investigators hypothesize the incidence of grade 3-4 neutropenia is 40%, with a of 0.05 and of 0.8, a sample size of 264 cases if needed.

Clinical Study Identifier: NCT02549677

Contact Investigators or Research Sites near you

Start Over

Yan Fang, doctor

Ruijin Hospital
Shanghai, China
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.